EBV-EA IgG ELISA Kit (DEIA329)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma
Species Reactivity
Human
Intended Use
The Epstein Barr Virus Early Antigen (EBV-EA) IgG Enzyme-linked Immunosorbent Assay (ELISA), is intended for the detection of IgG antibody to Epstein Barr Virus Nuclear Antigen-1 in human sera and plasma.
Contents of Kit
1. Microwell strips: EBV-EA antigen coated wells. (12 x 8 wells)
2. Sample Diluent: White Cap. 1 vial (22 ml)
3. Washing concentrate 10x: White Cap. 1bottle (100 ml)
4. TMB Chromogenic Substrate: Amber bottle. 1 vial (15 ml)
5. Enzyme conjugate: Red color solution. 1 vial (12 ml)
6. Negative control: Range stated on label. Natural Cap. 1 vial (150 µl)
7. Calibrator: Factor value (f) stated on label. Red Cap. 1 vial (150 µl)
8. Positive control: Range stated on label. Green Cap. 1 vial (150 µl)
9. Stop solution: 2 N HCl. 1 vial (12 ml)
Storage
Store the kit reagents at 2-8°C. Keep microwells sealed in a dry bag with desiccants. For more detailed information, please download the following document on our website.
Precision
The precision of the assay was evaluated by testing three different sera of eight replicates over a period of one week. The Intra-assay and Inter-assay C.V. are summarized below:
Intra-assay: Negative(12.5%) Low positive(8.5%) Positive(5.6%)
Inter-assay: Negative(14.8%) Low positive(10.9%) Positive(8.5%)

Citations


Have you cited DEIA329 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Extranodal NK/T Cell Lymphoma, Nasal Type with Palatal Involvement: A Rare Case Report and Literature Review

HEAD & NECK PATHOLOGY

Authors: Andreou, Anastasia; Thermos, Grigorios; Sklavounou-Andrikopoulou, Alexandra

T-cell lymphomas are infrequently encountered in the head and neck area, with the most common subtype being Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT). ENKTL-NT shows a predilection for midline facial structures presenting with ulcerative destructive lesions, whereas palatal involvement is one of the most prominent signs from the oral cavity. Herein, we describe a case of a 76-year-old Greek man with nasal obstruction and an extensive painful necrotic ulcer with ragged borders on the left distal portion of the soft palate and palatine tonsil of 4-months duration. After an initial non-diagnostic biopsy from the nasopharynx, a second incisional biopsy from the palatal lesions was performed. Histopathology was suggestive of an angiocentric lymphoproliferative neoplasm and immunohistochemical examination and in situ hybridization for EBV RNA led to a final diagnosis of ENKTL-NT. The patient was placed under combined chemotherapy and radiotherapy and no recurrence has been noted. Additionally, a retrospective review of the cases in the English literature with an established diagnosis of ENTKL-NT between 2000 and 2019, based on the latest WHO classification of Head and Neck tumors, is performed.

Smoking and Epstein-Barr virus infection in multiple sclerosis development

SCIENTIFIC REPORTS

Authors: Hedstrom, Anna Karin; Huang, Jesse; Brenner, Nicole; Butt, Julia; Hillert, Jan; Waterboer, Tim; Kockum, Ingrid; Olsson, Tomas; Alfredsson, Lars

It is unclear whether smoking interacts with different aspects of Epstein-Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case-control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2-0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI -0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004-0.4), but not between past smoking and IM history (AP -0.06, 95% CI -0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket